Eight pharmaceutical enterprises, including Sinopharm and steplength, are listed in the top 100 enterprises of Shaanxi in 2019!

[pharmaceutical network industry trends] at the end of the year, Shandong and other places released the list of local top 100 enterprises On December 3, the list of top 100 enterprises in Shaanxi Province in 2019 was released, which covers energy and chemical industry, equipment manufacturing, medicine, service industry, consumer goods and other industries in Shaanxi Province The data shows that the scale of top 100 enterprises in Shaanxi province continues to expand in 2019, and the economic benefits continue to grow Specifically, the total assets reached 43102 billion yuan; the total operating revenue exceeded 2 trillion yuan, reaching 20703 billion yuan In addition, the number of enterprises with an operating revenue of more than 100 billion yuan is 6, an increase of 2 compared with last year; the number of enterprises with an operating revenue of more than 10 billion yuan is 43, an increase of 11 compared with last year, which is ahead of time Among them, there are 8 pharmaceutical enterprises in the top 100 list Including Shaanxi pharmaceutical Holding Group Co., Ltd., Shaanxi Bikang Pharmaceutical Group Holding Co., Ltd., Xi'an Yikang pharmaceutical chain Co., Ltd., State Pharmaceutical holding Shaanxi Co., Ltd., Shaanxi step Pharmaceutical Co., Ltd., Shangyao Keyuan Xinhai Shaanxi Pharmaceutical Co., Ltd., Shaanxi Xihua Pharmaceutical Co., Ltd and Shaanxi Huayuan Pharmaceutical Group Co., Ltd
In terms of operating revenue, only one pharmaceutical enterprise of Shaanxi pharmaceutical Holding Group Co., Ltd has exceeded 20 billion yuan, and the operating revenue of the enterprise is about 20.6 billion yuan; there are two pharmaceutical enterprises with operating revenue of more than 5 billion yuan, namely Shaanxi Bikang Pharmaceutical Group Holding Co., Ltd and Xi'an Yikang pharmaceutical chain Co., Ltd.; the operating revenue of the other several pharmaceutical enterprises is between 2 billion and 5 billion yuan Billion yuan The author found that compared with the list of top 100 enterprises in Shaanxi in 2018, the ranking changed a lot this year Among them, Shaanxi pharmaceutical Holding Group Co., Ltd ranked 16 this year, 4 places higher than last year; Shaanxi Bikang Pharmaceutical Group Co., Ltd ranked 53, 5 places higher than last year; Shaanxi step Pharmaceutical Co., Ltd ranked 73, 10 places lower; Sinopharm Shaanxi Co., Ltd ranked 67, 12 places lower; Shangyao Keyuan Xinhai Shaanxi Pharmaceutical Co., Ltd ranked this year Shanxi Huayuan Pharmaceutical Group Co., Ltd ranked 97 this year, down 16 places compared with last year In 2019, there are two more pharmaceutical enterprises, Xi'an Yikang pharmaceutical chain Co., Ltd and Shaanxi Huashi pharmacy Co., Ltd., ranking 59 and 96 respectively According to the public information, Xi'an Yikang pharmaceutical chain Co., Ltd is a leading enterprise in the pharmaceutical retail industry in Northwest China It was founded in 2001 After nearly 8 years of rapid development, it has become a pharmaceutical chain enterprise with nearly 200 direct pharmaceutical chain stores and more than 100 franchise pharmaceutical chain stores It has nearly 10000 varieties of business and its business income is 6024.76 million yuan Shaanxi Huashi pharmacy Co., Ltd is a branch of Tianshi group which is mainly engaged in drug distribution in Northwest China The company's sales network realizes the full coverage of Xi'an, and it is also the centralized procurement and distribution enterprise of drugs and medical consumables in Gansu Province; and the "three unified" distribution work of drugs in some counties in Xi'an, Hanzhong, Weinan, Yan'an, Hancheng and other cities It is not hard to see that both enterprises belong to the field of pharmaceutical circulation In fact, since 2018, there have been frequent pharmaceutical policies such as volume procurement, increasing concentration of pharmaceutical circulation industry, and small and medium-sized enterprises gradually withdraw from the market It is generally believed in the industry that relevant leading enterprises of fine management are expected to benefit.